Overview
Tirzepatide is a synthetic dual agonist that targets both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. Originally investigated in large-scale clinical trials, it has become one of the most studied peptide compounds in metabolic research over the past five years.
Nova Biolabs stocks Tirzepatide 10mg in lyophilised (freeze-dried) form, held in UK domestic stock for fast dispatch. Each vial is research grade with high purity standards, suitable for laboratory and in vitro research use.
Key Research Areas
Incretin Receptor Pharmacology
Tirzepatide's dual mechanism makes it a valuable research tool for studying the synergistic effects of GLP-1 and GIP receptor activation, particularly in pancreatic beta cell models.
Metabolic Pathway Modulation
Studied extensively in laboratory models for its role in energy homeostasis, glucose signalling, and lipid metabolism pathway research.
Receptor Binding Kinetics
The compound's unique dual-receptor affinity profile makes it valuable for comparative receptor binding studies against single-agonist compounds.
Appetite Signalling Research
Investigated in cellular models for its interaction with appetite-regulating pathways, including hypothalamic signalling cascades.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 10mg per vial |
| Purity | >98% (HPLC verified) |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |